Insulin resistance: Impact on therapeutic developments in diabetes

Clifford J. Bailey*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalDiabetes and Vascular Disease Research
Issue number2
Publication statusPublished - 23 Apr 2019

Bibliographical note

© Sage 2019. The final publication is available via Sage at


  • diabetes therapies
  • dipeptidyl peptidase-4 inhibitors
  • glucagon-like peptide-1 receptor agonists
  • insulin
  • Insulin resistance
  • metformin
  • sulfonylureas
  • thiazolidinediones


Dive into the research topics of 'Insulin resistance: Impact on therapeutic developments in diabetes'. Together they form a unique fingerprint.

Cite this